Imatinib has been shown to induce apoptosis in BCR-ABL-negative CLL lymphocytes at clinically relevant concentrations, potentially through interaction with c-abl and the proapoptotic protein Par-4 [18]. The gene discussed is ABL1; the disease is B-cell chronic lymphocytic leukemia.